Skip to content

Intranasal Sufentanil Pain-management at Entrance of Emergency Department : Influence on Pain-relief Delay

Acute Severe Traumatic Pain in the ED : Can we Improve Time to Pain-relief With a Single Dose of Intranasal Sufentanil Given at Triage ? A Randomized Double-blinded Placebo Controlled Study (InSPEED Study)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01954368
Acronym
InSPEED
Enrollment
144
Registered
2013-10-01
Start date
2014-01-31
Completion date
2016-03-31
Last updated
2016-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Single Traumatic Limb Injury With Severe Pain (Score > 5/10 on Numerical Pain Scale)

Brief summary

Non-invasive and simple, intranasal (IN) route of administration seems promising for pain management in the Emergency Department (ED), especially when used precociously by triage nurse to rapidly deliver the first opioid dose to severely painful patients. This randomized double-blind placebo-controlled study will focus on severe traumatic pain experienced by adults admitted in our ED. We hypothesized that, in addition to traditional morphine titration, a single dose of IN sufentanil given at triage would significantly increase the proportion of patients relieved 30 minutes after their ED admission. Time to discharge, proportion of side effects and satisfaction rates will also be recorded.

Detailed description

Time to pain-relief can vary widely in the Emergency Department (ED), depending on various factors such as ED overcrowding or inadequate training in pain management. As intravenous (IV) opioid administration is world-wide recommended for severe pain treatment, delays from triage to room admission and to first IV injection directly influence this time to pain-relief. Moreover, it is proven that an incorrect adherence to morphine titration protocol can participate in ED oligoanalgesia. Although ED experience in intranasal (IN) opioid administration is still lacking, this simple and non-invasive way of treating pain seems safe and promising. Opioid pharmacokinetic by IN route indeed is interesting for ED practitioners : while assuring a timely analgesia, the lower Cmax and delayed Tmax by IN route can theoretically limit the risk of respiratory depression, in comparison with IV route. We propose a randomized double-blind placebo-controlled study on a convenience sample of adult patients admitted in our ED (annual census of 80000 attendances) for an isolated limb injury, and experiencing a severe pain (score \> 5/10 on numerical pain scale). For primary outcome, we will compare the proportion of patients relieved (score \< 4/10) 30 minutes after admission, depending on the administration (or not) of a single intranasal dose of sufentanil (0,4 mcg/kg) given by the triage nurse. Other secondary outcomes will include : evolution of pain scores in the first hour of admission and during entire ED stay, proportions of opioid-induced side-effects, proportions of patients receiving morphine and doses of morphine administrated, times for discharge, patient and staff satisfaction scores.

Interventions

DRUGPlacebo

As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution). Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.

DRUGSufentanil

As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil. Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Single traumatic limb injury. * Severe pain (score \> 5/10 on numerical pain scale) * Age ≥ 18 years and \< 75 years

Exclusion criteria

* Abdominal, thoracic, vertebral or cranial injury associated * Hemodynamic instability (systolic blood pressure \< 100 mmHg and/or blood pulse \> 110 / min) * Oxygen saturation \< 96% on room air * Chronic respiratory, renal or cardiac failure * Impaired mental status (Glasgow Coma Scale \< 15)

Design outcomes

Primary

MeasureTime frameDescription
Pain relief assessment30 minutes after ED admissionProportion of patients pain-relieved (score \< 4/10 on numerical pain scale) at T30 (30 minutes after their admission)

Secondary

MeasureTime frameDescription
Pain assessment30 minutes after ED admissionProportions of patients having a score on numerical pain scale \< 6/10 at room admission.
time to pain relief treatment30 minutes after ED admissionDelay from ED admission to first opioid injection (IV morphine or IN sufentanil).
Delay from first opioid injection to pain-relief30 minutesDelay from first opioid injection (IV morphine or IN sufentanil) to pain-relief.
opioids-related side-effects2h after last opioid injection.Proportions of opioids-related side-effects.
ED length of stay8 h after ED admissionED length of stay.
Nurse satisfactionat dischargeNurse satisfaction score at discharge (an average time of 12h)(on a zero-to-10 scale)
Patient satisfactionat dischargePatient satisfaction score at discharge (an average time of 12h) (on a zero-to-10 scale)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026